TransCode Therapeutics (NASDAQ: RNAZ) announced the initiation of a Phase 2a clinical trial evaluating its lead therapeutic candidate, TTX-MC138, in up to 45 colorectal cancer patients who remain circulating tumor DNA-positive following curative-intent therapy despite no radiographic evidence of disease, indicating minimal residual disease. Conducted in collaboration with Quantum Leap Healthcare Collaborative through its PRE-I-SPY clinical trial platform, the study will assess the biological and clinical activity of TTX-MC138 in reducing recurrence risk in this high-risk patient population.
This trial is significant because it targets a critical unmet need in colorectal cancer management: patients who have completed curative therapy but still harbor minimal residual disease, as evidenced by circulating tumor DNA, face a high risk of recurrence. Current standard of care often involves watchful waiting, with no approved therapies specifically for this indication. By intervening at this stage, TTX-MC138 may prevent or delay relapse, potentially improving overall survival and quality of life for these patients.
TTX-MC138 is designed to target microRNA-10b, a well-documented biomarker associated with metastasis. Overexpression of microRNA-10b is linked to tumor progression and metastatic spread, making it a promising target for therapeutic intervention. The Phase 2a trial will provide initial data on the drug's activity and safety in this specific patient population, building on earlier preclinical and clinical findings.
The collaboration with Quantum Leap Healthcare Collaborative and the use of the PRE-I-SPY platform are notable as they allow for efficient trial design and adaptive features, potentially accelerating the development process. This platform has been used successfully in breast cancer trials and is now being extended to other tumor types.
TransCode Therapeutics is a clinical-stage company focused on developing RNA-based therapeutics for high-risk and advanced cancers. The company's portfolio includes other first-in-class candidates designed to mobilize the immune system against cancer cells. For more information about TransCode Therapeutics, visit the company's newsroom at https://ibn.fm/RNAZ.
The full press release is available at https://ibn.fm/wuRri. This announcement underscores the growing interest in targeting minimal residual disease as a strategy to improve outcomes in colorectal cancer, a disease that remains a leading cause of cancer-related deaths worldwide.
